Low-molecular-weight heparin during pregnancy

Thrombosis Research
M Bazzan, V Donvito

Abstract

Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the puerperium. Pregnancy itself increases the risk of thromboembolic complications probably owing to a combination of hypercoagulability and venous stasis due to venous dilation. Recent studies have indicated that some serious obstetric complications are correlated with inherited or acquired thrombophilia. The prevalence of venous thromboembolism (VTE) has been extimated to be 1 per 1000-2000 pregnancies in retrospective studies. Anticoagulant treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), low-molecular-weight heparin (LMWH) and warfarin. Warfarin is teratogenous if administered between the 6th and the 12th week. LMWH is replacing UH in the prevention and treatment of VTE both outside and more recently during pregnancy with the same indications, and also for obstetric complications. This paper assesses the safety and efficacy of heparin therapy during pregnancy and the puerperium. Its cardiovascular and obstetric indications and regimens and maternal and fetal side-effects are also discussed.

References

Jun 18, 1977·British Medical Journal·M L OrmeA M Breckenridge
Apr 25, 1989·Thrombosis and Haemostasis·J S GinsbergR Burrows
Oct 1, 1989·Archives of Internal Medicine·J S GinsbergR Burrows
Apr 13, 1985·Lancet·M BeaufilsJ C Colau
Aug 1, 1983·The Journal of Pediatrics·R McKennaU Vasan
Jan 1, 1980·The American Journal of Medicine·J G HallK M Wilson
Oct 1, 1995·Obstetrics and Gynecology·L A Barbour, J Pickard
Aug 1, 1994·Obstetrics and Gynecology·U HögbergA Sandström
Jun 1, 1994·Obstetrical & Gynecological Survey·M D Fejgin, D L Lourwood
Feb 1, 1994·British Heart Journal·E Sbarouni, C M Oakley
Dec 1, 1996·Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery·K V JamesJ J Cranley
Nov 20, 1998·Chest·J S Ginsberg, J Hirsh
Jan 8, 1999·The New England Journal of Medicine·M J KupfermincJ B Lessing
Jan 8, 1999·The New England Journal of Medicine·B M Sibai
Jul 17, 1999·Lancet·J P Ng
Aug 24, 1999·British Journal of Obstetrics and Gynaecology·M D McCollI A Greer
Oct 8, 1999·Obstetrical & Gynecological Survey·W S Chan, J G Ray
Nov 16, 1999·American Journal of Obstetrics and Gynecology·H L CaseleR Venkataramanan
Dec 22, 1999·Obstetrical & Gynecological Survey·C J Lockwood
Mar 9, 2000·The New England Journal of Medicine·J C MeijersF R Rosendaal

❮ Previous
Next ❯

Citations

Nov 15, 2001·Current Opinion in Obstetrics & Gynecology·F Paruk, J Moodley
Dec 23, 2008·Translational Research : the Journal of Laboratory and Clinical Medicine·Ganga RamidiNaila Goldenberg
Aug 30, 2005·Annals of the New York Academy of Sciences·Guillermo Ruiz-Irastorza, Munther A Khamashta
Mar 8, 2003·Hematology·Caroline R Shiach
Apr 18, 2003·Anesthesiology Clinics of North America·Sharon Abramovitz, Yaakov Beilin
Jun 17, 2009·American Journal of Reproductive Immunology : AJRI·Shrimati Shetty, Kanjaksha Ghosh
Nov 6, 2007·American Journal of Obstetrics and Gynecology·Adam J DuhlUNKNOWN Pregnancy and Thrombosis Working Group
Nov 26, 2010·Fertility and Sterility·Charles J GlueckPing Wang
Nov 15, 2011·Best Practice & Research. Clinical Obstetrics & Gynaecology·Kelly McNameeRoy G Farquharson
Oct 22, 2004·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Charles J GlueckLuann Sieve
Jan 5, 2002·Pharmacoepidemiology and Drug Safety
Aug 31, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Omar M ShaabanSafwat A Salman
Mar 29, 2003·Current Medical Research and Opinion·Alexander D MakatsariaN V Dolgushina
Jan 12, 2007·International Anesthesiology Clinics·Yaakov Beilin, Sharon Abramovitz
Aug 9, 2003·Expert Opinion on Drug Safety·Enrico Bernardi, Paolo Prandoni
Jan 14, 2012·Obstetrics and Gynecology International·Milagros CruzAmanda Rocío Gonzalez-Ramirez
Jan 27, 2021·Taiwanese Journal of Obstetrics & Gynecology·Fangfei JiangXinmin Chen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
R L Bick
Fetal Diagnosis and Therapy
Sara De CarolisAlessandro Caruso
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
Elvira GrandoneMaurizio Margaglione
International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics
J BarP Merlob
Journal of Thrombosis and Haemostasis : JTH
J C Gris, Pierre Marès
© 2021 Meta ULC. All rights reserved